Switch to:
More From Other Websites
Vical's Antifungal Candidate VL-2397 Receives QIDP Status Aug 20 2015
FDA Grants Qualified Infectious Disease Product (QIDP) Designation to VL-2397, Vical's Antifungal... Aug 19 2015
FDA Grants Qualified Infectious Disease Product (QIDP) Designation to VL-2397, Vical's Antifungal... Aug 19 2015
VICAL INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or... Aug 07 2015
VICAL INC Financials Aug 06 2015
10-Q for Vical, Inc. Aug 01 2015
Vical reports 2Q loss Jul 30 2015
Vical reports 2Q loss Jul 30 2015
Vical Reports Second Quarter 2015 Financial Results and Progress in Key Development Programs Jul 30 2015
VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 30 2015
Vical Reports Second Quarter 2015 Financial Results and Progress in Key Development Programs Jul 30 2015
Vical Announces News Release and Conference Call Schedule for Second Quarter 2015 Financial Results Jul 23 2015
Vical Announces News Release and Conference Call Schedule for Second Quarter 2015 Financial Results Jul 23 2015
The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases Jun 25 2015
Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog Jun 24 2015
Vical Looks a Lot Less Vital Jun 24 2015
Vical downgraded by ROTH Capital Jun 23 2015
Vical's Herpes Vaccine Didn't Meet Primary Endpoint Jun 22 2015
Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine Jun 22 2015
VICAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 22 2015


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK